SCHEMBL21544852

SCHEMBL21544852

Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1S

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.58
▸ TP53 P04637 2/20 0.58
▸ GMNN O75496 1/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ NFKB1 P19838 1/20 0.58
▸ DNMT1 P26358 1/20 0.58
▸ THPO P40225 1/20 0.58
▸ MTOR P42345 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ BLM P54132 1/20 0.58
▸ HBB P68871 1/20 0.58
▸ PMP22 Q01453 1/20 0.58
▸ HPGD P15428 1/20 0.53
▸ ADORA3 P0DMS8 4/20 0.53
▸ ADORA2A P29274 3/20 0.53
▸ ADORA2B P29275 2/20 0.53
▸ DPP4 P27487 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ SLC28A1 O00337 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30852235 0.88 LMNA (0.59) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL23414481 0.88 LMNA (0.59) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL6395695 0.87 LMNA (0.58) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL873210 0.87 LMNA (0.58) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL27826042 0.87 LMNA (0.58) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL8185392 0.87 LMNA (0.58) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL8185399 0.87 LMNA (0.58) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL1979500 0.87 LMNA (0.58) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL6393071 0.87 TP53 (0.58) LMNATP53GMNNALDH1A1NFKB1
SCHEMBL28364179 0.86 TAS1R3 (0.61) ADORA1SMN1; SMN2NT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597924-B2 Genome editing systems comprising repair-modulating enzyme molecules and methods of their use EDITAS MEDICINE, INC. (US) 2023-03-07 — — US disclosed
US-20190345490-A1 GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE EDITAS MEDICINE, INC. 2019-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345490-A1 GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE DCLRE1B, MPG, FEN1 LMNA 1719/4885TP53 1504/4885GMNN 523/4885
US-11597924-B2 Genome editing systems comprising repair-modulating enzyme molecules and methods of their use DCLRE1B, MPG, FEN1 LMNA 1719/4885TP53 1504/4885GMNN 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback